# Formononetin-d<sub>3</sub>-1

Cat. No.: HY-N0183S4 Molecular Formula:  $C_{16}H_9D_3O_4$ Molecular Weight: 271.28 **FGFR** Target:

Pathway: Protein Tyrosine Kinase/RTK Storage: Powder -20°C 3 years

4°C 2 years In solvent -80°C 6 months

> -20°C 1 month

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro DMF : ≥ 30 mg/mL (110.59 mM)

> DMF: ≥ 30 mg/mL (110.59 mM) DMSO: ≥ 25 mg/mL (92.16 mM) DMSO : ≥ 25 mg/mL (92.16 mM)

DMF:PBS (pH 7.2) (1:1) :  $\geq$  0.5 mg/mL (1.84 mM) \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.6862 mL	18.4311 mL	36.8623 mL
	5 mM	0.7372 mL	3.6862 mL	7.3725 mL
	10 mM	0.3686 mL	1.8431 mL	3.6862 mL

Please refer to the solubility information to select the appropriate solvent.

## **BIOLOGICAL ACTIVITY**

Description Formononetin-d $_3$ -1 is the deuterium-labeled Formononetin (HY-N0183) $^{[1]}$ .

> Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to

affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

In Vitro

1]. Russak EM, et al. Impact of D	euterium Substitution on the Pharn	nacokinetics of Pharmaceutic	als. Ann Pharmacother. 2019 Feb	:53(2):211-216.
	Caution: Product has not been			
		x: 609-228-5909 ark Dr, Suite Q, Monmouth	E-mail: tech@MedChemExpre Junction, NJ 08852, USA	ess.com

Page 2 of 2 www.MedChemExpress.com